Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network

Hannah K. Knudsen, Amanda J. Abraham, J Aaron Johnson, Paul M. Roman

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

The National Drug Abuse Treatment Clinical Trials Network (CTN), a collaborative federal research initiative that brings together universities and community-based treatment programs (CTPs), has conducted multiple clinical trials of buprenorphine for opioid dependence. Part of the CTN's mission is to promote the adoption of evidence-based treatment technologies. Drawing on a data collected during face-to-face interviews with administrators from a panel of 206 CTPs, this research examines the adoption of buprenorphine over a 2-year period. These data indicated that the adoption of buprenorphine doubled between the baseline and 24-month follow-up interviews. Involvement in a buprenorphine protocol continued to be a strong predictor of adoption at the 2-year follow-up, although adoption of buprenorphine tripled among those CTPs without buprenorphine-specific protocol experience. For-profit CTPs and those offering inpatient detoxification services were more likely to adopt buprenorphine over time. A small percentage of programs discontinued using buprenorphine. These findings point to the dynamic nature of service delivery in community-based addiction treatment and the continued need for longitudinal studies of organizational change.

Original languageEnglish (US)
Pages (from-to)307-312
Number of pages6
JournalJournal of Substance Abuse Treatment
Volume37
Issue number3
DOIs
StatePublished - Oct 1 2009
Externally publishedYes

Fingerprint

Buprenorphine
Substance-Related Disorders
Clinical Trials
Therapeutics
Interviews
Organizational Innovation
Administrative Personnel
Research
Opioid Analgesics
Longitudinal Studies
Inpatients
Technology

Keywords

  • Adoption of innovations
  • Buprenorphine
  • Clinical Trials Network
  • Health services research

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Phychiatric Mental Health
  • Clinical Psychology
  • Psychiatry and Mental health

Cite this

Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network. / Knudsen, Hannah K.; Abraham, Amanda J.; Johnson, J Aaron; Roman, Paul M.

In: Journal of Substance Abuse Treatment, Vol. 37, No. 3, 01.10.2009, p. 307-312.

Research output: Contribution to journalArticle

Knudsen, Hannah K. ; Abraham, Amanda J. ; Johnson, J Aaron ; Roman, Paul M. / Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network. In: Journal of Substance Abuse Treatment. 2009 ; Vol. 37, No. 3. pp. 307-312.
@article{c2fe24903ffb46068633f340d8ebf7d7,
title = "Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network",
abstract = "The National Drug Abuse Treatment Clinical Trials Network (CTN), a collaborative federal research initiative that brings together universities and community-based treatment programs (CTPs), has conducted multiple clinical trials of buprenorphine for opioid dependence. Part of the CTN's mission is to promote the adoption of evidence-based treatment technologies. Drawing on a data collected during face-to-face interviews with administrators from a panel of 206 CTPs, this research examines the adoption of buprenorphine over a 2-year period. These data indicated that the adoption of buprenorphine doubled between the baseline and 24-month follow-up interviews. Involvement in a buprenorphine protocol continued to be a strong predictor of adoption at the 2-year follow-up, although adoption of buprenorphine tripled among those CTPs without buprenorphine-specific protocol experience. For-profit CTPs and those offering inpatient detoxification services were more likely to adopt buprenorphine over time. A small percentage of programs discontinued using buprenorphine. These findings point to the dynamic nature of service delivery in community-based addiction treatment and the continued need for longitudinal studies of organizational change.",
keywords = "Adoption of innovations, Buprenorphine, Clinical Trials Network, Health services research",
author = "Knudsen, {Hannah K.} and Abraham, {Amanda J.} and Johnson, {J Aaron} and Roman, {Paul M.}",
year = "2009",
month = "10",
day = "1",
doi = "10.1016/j.jsat.2008.12.004",
language = "English (US)",
volume = "37",
pages = "307--312",
journal = "Journal of Substance Abuse Treatment",
issn = "0740-5472",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network

AU - Knudsen, Hannah K.

AU - Abraham, Amanda J.

AU - Johnson, J Aaron

AU - Roman, Paul M.

PY - 2009/10/1

Y1 - 2009/10/1

N2 - The National Drug Abuse Treatment Clinical Trials Network (CTN), a collaborative federal research initiative that brings together universities and community-based treatment programs (CTPs), has conducted multiple clinical trials of buprenorphine for opioid dependence. Part of the CTN's mission is to promote the adoption of evidence-based treatment technologies. Drawing on a data collected during face-to-face interviews with administrators from a panel of 206 CTPs, this research examines the adoption of buprenorphine over a 2-year period. These data indicated that the adoption of buprenorphine doubled between the baseline and 24-month follow-up interviews. Involvement in a buprenorphine protocol continued to be a strong predictor of adoption at the 2-year follow-up, although adoption of buprenorphine tripled among those CTPs without buprenorphine-specific protocol experience. For-profit CTPs and those offering inpatient detoxification services were more likely to adopt buprenorphine over time. A small percentage of programs discontinued using buprenorphine. These findings point to the dynamic nature of service delivery in community-based addiction treatment and the continued need for longitudinal studies of organizational change.

AB - The National Drug Abuse Treatment Clinical Trials Network (CTN), a collaborative federal research initiative that brings together universities and community-based treatment programs (CTPs), has conducted multiple clinical trials of buprenorphine for opioid dependence. Part of the CTN's mission is to promote the adoption of evidence-based treatment technologies. Drawing on a data collected during face-to-face interviews with administrators from a panel of 206 CTPs, this research examines the adoption of buprenorphine over a 2-year period. These data indicated that the adoption of buprenorphine doubled between the baseline and 24-month follow-up interviews. Involvement in a buprenorphine protocol continued to be a strong predictor of adoption at the 2-year follow-up, although adoption of buprenorphine tripled among those CTPs without buprenorphine-specific protocol experience. For-profit CTPs and those offering inpatient detoxification services were more likely to adopt buprenorphine over time. A small percentage of programs discontinued using buprenorphine. These findings point to the dynamic nature of service delivery in community-based addiction treatment and the continued need for longitudinal studies of organizational change.

KW - Adoption of innovations

KW - Buprenorphine

KW - Clinical Trials Network

KW - Health services research

UR - http://www.scopus.com/inward/record.url?scp=69349089334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69349089334&partnerID=8YFLogxK

U2 - 10.1016/j.jsat.2008.12.004

DO - 10.1016/j.jsat.2008.12.004

M3 - Article

C2 - 19577406

AN - SCOPUS:69349089334

VL - 37

SP - 307

EP - 312

JO - Journal of Substance Abuse Treatment

JF - Journal of Substance Abuse Treatment

SN - 0740-5472

IS - 3

ER -